MET and non-small cell lung carcinoma: These signaling pathways ultimately lead to increases in cell proliferation, survival and motility.[7] Protein overexpression or gene amplification of MET has been implicated in the oncogenesis of various cancer types, especially lung cancer.[8, 9] Early data in a phase I clinical trial (NCT00585195) have indicated that crizotinib has potent anti-tumor activity in patients with advanced NSCLC with MET amplification.[10] However, acquired drug resistance inevitably occurs in the application of crizotinib just as with other targeted agents.